Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Rübben H[au]:

[Editorial]. Rübben H et al. Urologe A. (2018)

[Kidney cancer]. Rübben H et al. Urologe A. (2015)

[Geriatric assessment]. Fröhner M et al. Urologe A. (2015)

Search results

Items: 1 to 50 of 404

1.

[Upper urinary tract cancer].

Tschirdewahn S, Rübben H.

Urologe A. 2019 Jan;58(1):3-4. doi: 10.1007/s00120-018-0827-8. German. No abstract available.

PMID:
30666375
2.

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.

Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M.

Eur Urol. 2019 Apr;75(4):604-611. doi: 10.1016/j.eururo.2018.09.047. Epub 2018 Oct 15.

PMID:
30337060
3.

[Erratum to: How should urologists perform implantation of subcutaneous central venous port systems? A single center experience of 347 cases].

Schenck M, Michels-Oswald W, Tschirdewahn S, Rübben H, Vom Dorp F, Rose A, Panic A, Niedworok C, Rossi R.

Urologe A. 2018 Aug;57(8):968. doi: 10.1007/s00120-018-0720-5. German. No abstract available.

PMID:
29955911
4.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

5.

Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.

Al-Bayati M, Grueneisen J, Lütje S, Sawicki LM, Suntharalingam S, Tschirdewahn S, Forsting M, Rübben H, Herrmann K, Umutlu L, Wetter A.

Urol Int. 2018;100(2):164-171. doi: 10.1159/000484695. Epub 2018 Jan 25.

PMID:
29393268
6.

[Editorial].

Rübben H.

Urologe A. 2018 Jan;57(1):3. doi: 10.1007/s00120-017-0558-2. German. No abstract available.

PMID:
29357000
7.

Haematuria work-up in general care-A German observational study.

Eisenhardt A, Heinemann D, Rübben H, Heß J.

Int J Clin Pract. 2017 Aug;71(8). doi: 10.1111/ijcp.12982. Epub 2017 Jul 27.

PMID:
28750476
8.

Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder.

Hess J, Stelmach P, Eisenhardt A, Rübben H, Reis H, Schmid KW, Bachmann HS.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1659-1670. doi: 10.1007/s00432-017-2404-8. Epub 2017 Apr 17.

PMID:
28417194
9.

Integrated 68Ga-HBED-CC-PSMA-PET/MRI in patients with suspected recurrent prostate cancer.

Lütje S, Cohnen J, Gomez B, Grüneisen J, Sawicki L, Rübben H, Bockisch A, Umutlu L, Pöppel TD, Wetter A.

Nuklearmedizin. 2017 Jun 13;56(3):73-81. doi: 10.3413/Nukmed-0850-16-09. Epub 2017 Apr 12.

PMID:
28401244
10.

[Metastasized urological malignancies : Is resection of the primary tumor or destruction using alternative procedures worthwhile?]

Stief CG, Rübben H.

Urologe A. 2017 May;56(5):563. doi: 10.1007/s00120-017-0365-9. German. No abstract available.

PMID:
28337502
11.

[When is surgical treatment indicated in metastatic urothelial carcinoma and what is the scientific rationale?]

Niedworok C, Rübben H.

Urologe A. 2017 May;56(5):585-590. doi: 10.1007/s00120-017-0362-z. Review. German.

PMID:
28321462
12.

Progression-related loss of stromal Caveolin 1 levels fosters the growth of human PC3 xenografts and mediates radiation resistance.

Panic A, Ketteler J, Reis H, Sak A, Herskind C, Maier P, Rübben H, Jendrossek V, Klein D.

Sci Rep. 2017 Jan 23;7:41138. doi: 10.1038/srep41138.

13.

Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival.

Niedworok C, Tschirdewahn S, Reis H, Lehmann N, Szücs M, Nyirády P, Romics I, Rübben H, Szarvas T.

Pathol Oncol Res. 2017 Jul;23(3):643-650. doi: 10.1007/s12253-016-0171-5. Epub 2016 Dec 23.

PMID:
28012116
14.

[Social support in gender reassignment surgery].

Hess J, Kurth I, Henkel A, Panic L, Rübben H, Rossi Neto R, Hess-Busch Y.

Urologe A. 2017 Feb;56(2):186-193. doi: 10.1007/s00120-016-0261-8. German.

PMID:
27830287
15.

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.

Módos O, Reis H, Niedworok C, Rübben H, Szendröi A, Szász MA, Tímár J, Baghy K, Kovalszky I, Golabek T, Chlosta P, Okon K, Peyronnet B, Mathieu R, Shariat SF, Hollósi P, Nyirády P, Szarvas T.

Oncotarget. 2016 Jun 28;7(26):39293-39301. doi: 10.18632/oncotarget.9828.

16.

[Karyometry of BBN-induced precancerosis of the urothelium : An experimental analysis].

Dahm HH, Lehnen-Holtum V, Rübben H.

Urologe A. 2016 Oct;55(10):1329-1334. German.

PMID:
27246476
17.

[Focal therapy].

Rübben H, Stief CG.

Urologe A. 2016 May;55(5):583. doi: 10.1007/s00120-016-0106-5. German. No abstract available.

PMID:
27130183
18.

[Organ-sparing treatment of bladder cancer].

Niedworok C, Shaleva A, Rübben H, Stenzl A.

Urologe A. 2016 May;55(5):609-14. doi: 10.1007/s00120-016-0086-5. Review. German.

PMID:
27119956
19.

Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancer.

Szarvas T, Reis H, Vom Dorp F, Tschirdewahn S, Niedworok C, Nyirady P, Schmid KW, Rübben H, Kovalszky I.

Prostate. 2016 Aug;76(11):977-85. doi: 10.1002/pros.23186. Epub 2016 Apr 7.

PMID:
27062540
20.

DNA cytophotometric and histological analysis of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced precancerous lesions of the bladder urothelium.

Dahm HH, von der Haar C, Rübben H.

J Cancer Res Clin Oncol. 2016 Jun;142(6):1253-60. doi: 10.1007/s00432-016-2153-0. Epub 2016 Mar 31.

21.

Modified Preparation of the Neurovascular Bundle in Male to Female Transgender Patients.

Hess J, Hess-Busch Y, Kronier J, Rübben H, Rossi Neto R.

Urol Int. 2016;96(3):354-9. doi: 10.1159/000443281. Epub 2016 Jan 19.

PMID:
26780212
22.

Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method.

Niedworok C, vom Dorp F, Tschirdewahn S, Rübben H, Reis H, Szucs M, Szarvas T.

Int Urol Nephrol. 2016 Mar;48(3):355-61. doi: 10.1007/s11255-015-1185-8. Epub 2016 Jan 2.

PMID:
26725072
23.

[Geriatric assessment].

Fröhner M, Rübben H.

Urologe A. 2015 Dec;54(12):1699-700. doi: 10.1007/s00120-015-4028-4. German. No abstract available.

PMID:
26704272
24.

Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis.

Niedworok C, Panitz M, Szarvas T, Reis H, Reis AC, Szendröi A, Nyirády P, Szasz AM, Módos O, Rübben H, Vom Dorp F.

J Urol. 2016 Jun;195(6):1690-6. doi: 10.1016/j.juro.2015.11.067. Epub 2015 Dec 8.

PMID:
26678957
25.

Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer.

Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T.

J Urol. 2016 Apr;195(4 Pt 1):1120-5. doi: 10.1016/j.juro.2015.09.084. Epub 2015 Oct 8.

PMID:
26454102
26.

[Narrow band imaging-assisted cystoscopy in bladder tumor follow-up: Can more tumors be identified?].

Hirner L, Stagge E, Rübben H, Schenck M, Eisenhardt A.

Urologe A. 2016 Mar;55(3):370-5. doi: 10.1007/s00120-015-3942-9. German.

PMID:
26370096
27.

Risk and timing of biochemical recurrence in pT3aN0/Nx prostate cancer with positive surgical margin - A multicenter study.

Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, Ganzer R, Wieland W, Eder F, Hofstädter F, Schilling D, Sievert KD, Stenzl A, Scharpf M, Fend F, Vom Dorp F, Rübben H, Schmid KW, Porres-Knoblauch D, Heidenreich A, Hangarter B, Knüchel-Clarke R, Rogenhofer M, Wullich B, Hartmann A, Comploj E, Pycha A, Hanspeter E, Pehrke D, Sauter G, Graefen M, Gratzke C, Stief C, Wiegel T, Haese A.

Radiother Oncol. 2015 Jul;116(1):119-24. doi: 10.1016/j.radonc.2015.06.021. Epub 2015 Jun 29.

PMID:
26138059
28.

[Kidney cancer].

Rübben H.

Urologe A. 2015 Jun;54(6):799. doi: 10.1007/s00120-015-3874-4. German. No abstract available.

PMID:
26081816
29.

[Genetic aspects of erectile dysfunction].

Eisenhardt A, Sperling H, Rübben H.

Urologe A. 2015 May;54(5):662-7. doi: 10.1007/s00120-015-3793-4. Review. German.

PMID:
25987331
30.

Complete transection of the urethra and corpora cavernosa: a complication after laparoscopic repair (TEP) of an inguinal hernia.

Rehme C, Rübben H, Heß J.

Hernia. 2016 Jun;20(3):493-5. doi: 10.1007/s10029-015-1388-z. Epub 2015 May 6.

PMID:
25943096
31.

Effects of a 15-Month Supervised Exercise Program on Physical and Psychological Outcomes in Prostate Cancer Patients Following Prostatectomy: The ProRehab Study.

Zopf EM, Bloch W, Machtens S, Zumbé J, Rübben H, Marschner S, Kleinhorst C, Schulte-Frei B, Herich L, Felsch M, Predel HG, Braun M, Baumann FT.

Integr Cancer Ther. 2015 Sep;14(5):409-18. doi: 10.1177/1534735415583552. Epub 2015 Apr 27.

PMID:
25917814
32.

Mistletoe Plant Extract in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation Study.

Rose A, El-Leithy T, vom Dorp F, Zakaria A, Eisenhardt A, Tschirdewahn S, Rübben H.

J Urol. 2015 Oct;194(4):939-43. doi: 10.1016/j.juro.2015.04.073. Epub 2015 Apr 22.

PMID:
25910967
33.

[Nonmuscle-invasive bladder cancer].

Vom Dorp F, Lümmen G, Rübben H.

Urologe A. 2015 Apr;54(4):479. doi: 10.1007/s00120-015-3828-x. German. No abstract available.

PMID:
25895561
34.

[Treatment of bladder cancer in the elderly].

Fröhner M, Rübben H.

Urologe A. 2015 Apr;54(4):510-5. doi: 10.1007/s00120-015-3777-4. German.

PMID:
25794588
35.

The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence.

Karl A, Buchner A, Tympner C, Kirchner T, Ganswindt U, Belka C, Ganzer R, Burger M, Eder F, Hofstädter F, Schilling D, Sievert K, Stenzl A, Scharpf M, Fend F, Vom Dorp F, Rübben H, Schmid K, Porres-Knoblauch D, Heidenreich A, Hangarter B, Knüchel-Clarke R, Rogenhofer M, Wullich B, Hartmann A, Comploj E, Pycha A, Hanspeter E, Pehrke D, Sauter G, Graefen M, Stief C, Haese A.

World J Urol. 2015 Jul;33(7):973-9. doi: 10.1007/s00345-015-1510-y. Epub 2015 Feb 15.

PMID:
25682109
36.

Satisfaction with male-to-female gender reassignment surgery.

Hess J, Rossi Neto R, Panic L, Rübben H, Senf W.

Dtsch Arztebl Int. 2014 Nov 21;111(47):795-801. doi: 10.3238/arztebl.2014.0795.

37.

Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters.

Niedworok C, Dörrenhaus B, Vom Dorp F, Piotrowski JA, Tschirdewahn S, Szarvas T, Rübben H, Schenck M.

World J Urol. 2015 Oct;33(10):1541-52. doi: 10.1007/s00345-014-1449-4. Epub 2014 Nov 30.

PMID:
25433505
38.

[Non-muscle invasive bladder cancer: safety of postoperative EMDA-assisted instillation of mitomycin].

Rehme C, Niedworok C, Rübben H, Vom Dorp F.

Urologe A. 2015 Feb;54(2):235-8. doi: 10.1007/s00120-014-3649-3. German.

PMID:
25316185
39.

Benefits and risks of prostate cancer screening.

Fornara P, Theil G, Schaefer C, Heß J, Rübben H.

Oncol Res Treat. 2014;37 Suppl 3:29-37. doi: 10.1159/000363756. Epub 2014 Aug 29. No abstract available.

40.

[Organ- and function-preserving surgery in urological tumors].

Rübben H.

Urologe A. 2014 Sep;53(9):1283. doi: 10.1007/s00120-014-3631-0. German. No abstract available.

PMID:
25159336
41.

[Transitional cell carcinoma of the bladder: bladder-sparing therapy].

Vom Dorp F, Tschirdewahn S, Szarvas T, Rübben H, Kraemer R, Rehme C.

Urologe A. 2014 Sep;53(9):1322-8. doi: 10.1007/s00120-014-3554-9. German. Erratum in: Urologe A. 2014 Dec;53(12):1804. Kraemer, R [added].

PMID:
25148911
42.

[Organ and kidney function preservation in renal cell carcinoma].

Schenck M, Eder R, Rübben H, Niedworok C, Tschirdewahn S.

Urologe A. 2014 Sep;53(9):1329-43. doi: 10.1007/s00120-014-3558-5. German.

PMID:
25142788
43.

[Therapeutic concepts for the treatment of metastatic urologic diseases].

Rübben H.

Urologe A. 2014 Jun;53(6):801. doi: 10.1007/s00120-014-3527-z. German. No abstract available.

PMID:
24845013
44.

Prognostic effect of serum and tissue YKL-40 levels in bladder cancer.

Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendröi A, Schmid KW, Shariat SF, Kramer G, vom Dorp F, Rübben H, Szarvas T.

Urol Oncol. 2014 Jul;32(5):663-9. doi: 10.1016/j.urolonc.2014.02.004. Epub 2014 May 9.

PMID:
24814404
46.

Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer.

Szarvas T, Reis H, Kramer G, Shariat SF, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübben H.

Hum Pathol. 2014 Apr;45(4):674-82. doi: 10.1016/j.humpath.2013.10.036. Epub 2013 Dec 18.

PMID:
24656090
47.

Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.

Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, Shariat SF, Rübben H, vom Dorp F.

Int J Cancer. 2014 Oct 1;135(7):1596-604. doi: 10.1002/ijc.28808. Epub 2014 Mar 4.

48.

Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis.

Wetter A, Lipponer C, Nensa F, Heusch P, Rübben H, Schlosser TW, Pöppel TD, Lauenstein TC, Nagarajah J.

Ann Nucl Med. 2014 Jun;28(5):405-10. doi: 10.1007/s12149-014-0825-x. Epub 2014 Mar 5.

PMID:
24595461
49.

[Childhood ureteropelvic junction obstruction in a regional treatment center: spectrum and therapy].

Eisenhardt A, Rübben H, Rübben I, Dakkak D, Hoyer PF, Büscher R.

Urologe A. 2013 Dec;52(12):1698-704. doi: 10.1007/s00120-013-3346-7. German.

PMID:
24258353
50.

Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.

Niedworok C, Röck K, Kretschmer I, Freudenberger T, Nagy N, Szarvas T, Vom Dorp F, Reis H, Rübben H, Fischer JW.

PLoS One. 2013 Nov 6;8(11):e80084. doi: 10.1371/journal.pone.0080084. eCollection 2013.

Supplemental Content

Loading ...
Support Center